MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Accounts Receivables 2011-2026 | ILMN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 735 M | 734 M | 648 M | 487 M | - | 573 M | 514 M | 411 M | 386 M | - | 289 M | 239 M | 215 M | 166 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 735 M | 166 M | 450 M |
Quarterly Accounts Receivables Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 729 M | 701 M | - | 641 M | 635 M | 741 M | 665 M | 671 M | - | 642 M | 614 M | 487 M | 604 M | 540 M | 517 M | - | 464 M | 385 M | 472 M | 573 M | 573 M | 573 M | 573 M | 514 M | 514 M | 514 M | 514 M | 411 M | 411 M | 411 M | 411 M | 386 M | 382 M | 372 M | 403 M | - | 413 M | 369 M | 350 M | 289 M | 289 M | 289 M | 289 M | 239 M | 239 M | 239 M | 239 M | 215 M | 215 M | 215 M | 215 M | 166 M | 169 M | 193 M | 182 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 741 M | 166 M | 429 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
173 K | $ 3.05 | -1.62 % | $ 99 K |  USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 34.5 | 2.16 % | $ 371 M |  China |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.24 | -15.65 % | $ 1.58 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 39.73 | 1.44 % | $ 1.1 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
3.54 B | $ 219.15 | -0.14 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
249 M | $ 102.44 | 0.13 % | $ 19 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
69 M | $ 26.14 | -0.38 % | $ 790 M | USA |
 |
Guardant Health
GH
|
110 M | $ 113.64 | 2.86 % | $ 13.9 B | USA |
 |
DexCom
DXCM
|
974 M | $ 73.4 | -0.81 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
51.1 M | $ 20.69 | -0.53 % | $ 1.11 B | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 9.94 | -3.54 % | $ 282 M |  Israel |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
321 M | $ 66.97 | 0.44 % | $ 4.63 B | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
151 M | $ 12.04 | -2.9 % | $ 1.52 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
3.2 B | $ 231.17 | -1.83 % | $ 41.9 B | USA |
 |
Charles River Laboratories International
CRL
|
721 M | $ 210.54 | -0.57 % | $ 10.8 B | USA |
 |
Medpace Holdings
MEDP
|
296 M | $ 585.64 | -1.25 % | $ 18.1 B | USA |
 |
Personalis
PSNL
|
8.14 M | $ 9.43 | -5.42 % | $ 559 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 186.85 | 2.49 % | $ 20.7 B | USA |
|
Biodesix
BDSX
|
8.6 M | $ 9.94 | 2.85 % | $ 1.29 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
1.3 M | $ 24.53 | 1.11 % | $ 31.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 271.48 | 0.62 % | $ 22.8 B | USA |
 |
Mettler-Toledo International
MTD
|
687 M | $ 1 381.85 | -0.79 % | $ 29.3 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 180.78 | -2.75 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
474 M | $ 674.26 | -0.36 % | $ 55.6 B | USA |
 |
Agilent Technologies
A
|
1.17 B | $ 133.38 | 0.11 % | $ 40.5 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.36 | -1.26 % | $ 5.42 M | USA |